Imunon Valuation
| IMNN Stock | USD 3.25 0.02 0.61% |
At this time, the firm appears to be undervalued. Imunon Inc retains a regular Real Value of $7.72 per share. The prevalent price of the firm is $3.25. Our model calculates the value of Imunon Inc from evaluating the firm fundamentals such as Shares Owned By Insiders of 1.05 %, return on asset of -0.78, and Return On Equity of -2.33 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Imunon's valuation include:
Price Book 2.8699 | Enterprise Value | Enterprise Value Ebitda 0.9097 | Price Sales 17.9405 | Enterprise Value Revenue 4.0043 |
Undervalued
Today
Please note that Imunon's price fluctuation is slightly risky at this time. Calculation of the real value of Imunon Inc is based on 3 months time horizon. Increasing Imunon's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Imunon is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Imunon Stock. However, Imunon's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.25 | Real 7.72 | Target 21.5 | Hype 3.24 |
The intrinsic value of Imunon's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Imunon's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Imunon Inc helps investors to forecast how Imunon stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Imunon more accurately as focusing exclusively on Imunon's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Imunon's intrinsic value based on its ongoing forecasts of Imunon's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Imunon's closest peers.
Imunon Cash |
|
Imunon Total Value Analysis
Imunon Inc is currently estimated to have valuation of 7.57 M with market capitalization of 11.63 M, debt of 1.14 M, and cash on hands of 42.11 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Imunon fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
7.57 M | 11.63 M | 1.14 M | 42.11 M |
Imunon Asset Utilization
One of the ways to look at asset utilization of Imunon is to check how much profit was generated for every dollar of assets it reports. Imunon retains a negative application of resources of -0.78 (percent), losing $0.007772 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Imunon Inc shows how discouraging it operates for each dollar spent on its resources.Imunon Profitability Analysis
Considering Imunon's profitability and operating efficiency indicators, Imunon Inc may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Imunon's ability to earn profits and add value for shareholders.Net Loss | First Reported 1996-09-30 | Previous Quarter -2.7 M | Current Value -3.4 M | Quarterly Volatility 5.1 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.35 | 0.37 |
|
|
For Imunon profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Imunon Inc to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Imunon utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Imunon's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Imunon over time as well as its relative position and ranking within its peers.
Imunon Earnings per Share Projection vs Actual
The next projected EPS of Imunon is estimated to be -3.638125 with future projections ranging from a low of -10.4625 to a high of -0.66. Imunon's most recent 12-month trailing earnings per share (EPS TTM) is at -12.53. Please be aware that the consensus of earnings estimates for Imunon Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.Imunon Earnings Estimation Breakdown
The calculation of Imunon's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Imunon is estimated to be -3.638125 with the future projection ranging from a low of -10.4625 to a high of -0.66. Please be aware that this consensus of annual earnings estimates for Imunon Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-10.46 Lowest | Expected EPS | -0.66 Highest |
Imunon Earnings Projection Consensus
Suppose the current estimates of Imunon's value are higher than the current market price of the Imunon stock. In this case, investors may conclude that Imunon is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Imunon's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 4 | 65.56% | -1.16 | -3.638125 | -12.53 |
Imunon Ownership Allocation
The market capitalization of Imunon is $11.63 Million. Roughly 93.63 (percent) of Imunon outstanding shares are held by general public with 1.05 % owned by insiders and only 5.32 pct. by outside corporations. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Imunon Profitability Analysis
Net Loss for the year was (18.62 M) with profit before overhead, payroll, taxes, and interest of 2.72 M.About Imunon Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Imunon Inc. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Imunon Inc based exclusively on its fundamental and basic technical indicators. By analyzing Imunon's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Imunon's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Imunon. We calculate exposure to Imunon's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Imunon's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -646.3 K | -614 K | |
| Pretax Profit Margin | (86.17) | (81.86) | |
| Operating Profit Margin | (44.86) | (47.10) | |
| Net Loss | (64.62) | (67.85) | |
| Gross Profit Margin | 0.37 | 0.35 |
Imunon Current Valuation Indicators
Imunon's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Imunon's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Imunon, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Imunon's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Imunon's worth.When determining whether Imunon Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Imunon's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Imunon Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Imunon Inc Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Will Biotechnology sector continue expanding? Could Imunon diversify its offerings? Factors like these will boost the valuation of Imunon. Market participants price Imunon higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Imunon data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Imunon Inc requires distinguishing between market price and book value, where the latter reflects Imunon's accounting equity. The concept of intrinsic value - what Imunon's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Imunon's price substantially above or below its fundamental value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Imunon's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.